Pramlintide
Also known as: Pramlintide acetate, Symlin, SymlinPen
Classification
Peptide
Regulatory Status
FDA-approved (historical Symlin labeling; check current marketing status)
Sources
3
Review
n/a
Overview
Pramlintide is a synthetic analog of human amylin co-secreted with insulin; as labeled adjunctive therapy it helps regulate postprandial glucose when used with mealtime insulin.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
FDA-approved (Symlin/pramlintide acetate) as adjunctive treatment for patients with type 1 or type 2 diabetes using mealtime insulin who have not achieved desired glucose control. Some presentations have been listed discontinued on Drugs@FDA; historical labeled use remains the evidence anchor. Educational reference only.
Interactions & cautions
Drug interactions
mealtime insulin — Increased risk of severe hypoglycemia; altered absorption of some concomitant oral agents is a labeled concern. (high)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw